fbpx
  • About us
  • Advertise
  • Contact
  • Nominate
  • Client’s Voice
  • Login
  • Register
📖 Magazine
The Global Economics
  • Home
  • Banking
  • Non Banking
  • Markets
  • Infrastructure
  • Lifestyle
  • FeatureNew
  • Awards
No Result
View All Result
  • Home
  • Banking
  • Non Banking
  • Markets
  • Infrastructure
  • Lifestyle
  • FeatureNew
  • Awards
No Result
View All Result
The Global Economics
No Result
View All Result
Home Non Banking Mergers & Acquisitions

Adragos Pharma to acquire Sanofi’s 50-year-old manufacturing site in Kawagoe in Japan

Adragos Pharma will now be positioned amongst the top 3 biggest pureplay CDMOs in Japan

Ritu M R by Ritu M R
October 14, 2022
in Mergers & Acquisitions, The Global Economics, Top Stories
Reading Time: 3 mins read
0
Adragos Pharma to acquire Sanofi’s 50-year-old manufacturing site in Kawagoe in Japan. (Image Source : Adragos Pharma)

Adragos Pharma to acquire Sanofi’s 50-year-old manufacturing site in Kawagoe in Japan. (Image Source : Adragos Pharma)

30
SHARES
164
VIEWS
FacebookTwitterRedditWhatsAppLinkedInShare Link

Adragos Pharma, a globally operating Contract Development and Manufacturing Organisation (CDMO) based in Munich, Germany signed definitive agreements with Sanofi K.K. for the acquisition of a pharmaceutical manufacturing site in Kawagoe, in proximity to Tokyo, Japan.

Adragos Pharma will also enter a long-term supply pact with Sanofi K.K, thereby becoming a strategic partner for Sanofi in the Japanese market. Additionally, Adragos Pharma will bring together new customers to the manufacturing site from Europe, and North America inclusive of the domestic Japanese market. Their second investment in the region, Adragos Pharma will now be positioned amongst the top 3 biggest pureplay CDMOs in Japan.

Sanofi and the German CDMO, Adragos Pharma signed the definitive agreements for the transfer of ownership of one of Sanofi’s manufacturing sites in Japan. The site located in Kawagoe has over 50 years of pharmaceutical manufacturing history. Sanofi’s site manufactured oral solids, visual inspection, and sterile liquids, and conducted packing and retesting services for the Asian and Japanese markets.

Under a long-term supply agreement, Adragos Pharma will further continue to manufacture for Sanofi and become its strategic partner for the Japanese market. Adragos Pharma has considered Japan to be one of the three core markets. The Kawagoe site is headed by a well-experienced site leadership team and features a very well-trained workforce, who will all continue to stay at the site. Adragos Pharma aims to further expand the site’s capabilities and services for Sanofi and its upcoming customers, starting production capabilities in the Japanese market and supporting its mission to facilitate access to affordable, high-quality medication.

Jeremy Goldnadel, International & Europe Cluster Head, Industrial Affairs, Sanofi stated that the company is delighted to partner with Adragos Pharma to continue delivering the highest quality products in the long term and further develop the manufacturing site. It firmly believes that the Kawagoe site with its employees will continue to practice the similar strive for excellence with Adragos Pharma, all the way through a new journey that would bring about the most value to their customers and patients in Japan.

Noting the acquisition as a key pillar in building a globally leading CDMO, Dr. Andreas Raabe, CEO at Adragos Pharma, stated that the team is very gratified and honored to further strengthen their excellent relationship with Sanofi. Japan is positioned amongst the largest and most alluring global pharma markets, nevertheless, CDMO activities are relatively burgeoning. With Kawagoe, the company offers tremendous capabilities to its domestic and international consumers.

Marco Gorgas, CTO at Adragos Pharma, stated that the firm is deeply impressed with the site’s workforce and capabilities, which will offer a solid platform for future growth. Gorgas added that Sanofi and its new customers can rely on their full commitment to offering a reliable supply of affordable and exceptional products for the patients. The company has not disclosed the detailed terms of the transaction. The transaction is subject to customary provisions guidelines.

About Adragos

Adragos Pharma is a globally operating CDMO headquartered in Munich, Germany. Its stated objective is to expand its existing production system all through acquisitions in Europe, Japan, and North America to achieve a worldwide leading position within the next few years and set new standards for data centricity and customer service. Adragos Pharma is supported by FSN Capital, a leading Northern European private equity firm, and Prange Group, a diversified leading German family office in its buy-and-build growth approach. Adragos Pharma at present operates three production sites in France, Japan, and Germany.

About Sanofi

Sanofi is an innovative global healthcare company. A limited liability firm unified under the laws of France with securities listed on Euronext Paris, the U.S., and France Nasdaq Global Select Market (Nasdaq). The team spans some 100 countries and is dedicated to transforming the exercise of medicine by working to change the impractical into the viable. The company provides potentially life-changing treatment options and life-saving vaccine protection to millions of people worldwide while placing sustainability and social responsibility at the center of their aspirations.

Tags: Adragos PharmaCDMOGermanyjapanSanofi
Ritu M R

Ritu M R

Ritu is a professional who aims at writing informative and engaging articles that appeal to the readers.

Related Posts

Hungary nears agreement with European Union to access nearly $ 30 billion frozen funds
Funds

Hungary nears agreement with European Union to access nearly $ 30 billion frozen funds

by Riya Thomas
March 24, 2023
China’s March Towards Automobile Dominance
Clean Energy

China’s March Towards Automobile Dominance

by The Global Economics
March 24, 2023
Housing Risk in South Korea Worsened Due to Bizarre $828 Billion Loan Market
Real Estate

Housing Risk in South Korea Worsened Due to Bizarre $828 Billion Loan Market

by Rahil Adnan
March 24, 2023
Ford’s Electric Vehicle Unit Forecasts $3 Billion Loss in 2023
Transportation

Ford’s Electric Vehicle Unit Forecasts $3 Billion Loss in 2023

by Riya Thomas
March 24, 2023
40% Rise in Puig Annual Revenues up to €3.6 billion, in 2022
Fashion

Puig Annual Revenues Skyrocket 40% up to €3.6 billion, in 2022

by Rahil Adnan
March 24, 2023
Previous
Next
Facebook Twitter Instagram Youtube LinkedIn Soundcloud
The Global Economics

The Global Economics Limited is a UK based financial publication and a quarterly business magazine giving thoughtful insights into the financial sectors on various industries across the world. Our highlight is the prestigious country specific Annual Global Economics awards program where the best performers in various financial sectors are identified worldwide and honoured.

DMCA.com Protection Status

  • Privacy
  • Legal
  • Terms of Use
  • Client’s Voice
  • Server Status

norton verified - the global economics

Latest Posts

Hungary nears agreement with European Union to access nearly $ 30 billion frozen funds

Hungary nears agreement with European Union to access nearly $ 30 billion frozen funds

March 24, 2023
China’s March Towards Automobile Dominance

China’s March Towards Automobile Dominance

March 24, 2023
Housing Risk in South Korea Worsened Due to Bizarre $828 Billion Loan Market

Housing Risk in South Korea Worsened Due to Bizarre $828 Billion Loan Market

March 24, 2023
Download The Global Economics PWA to your mobile or Desktop
PWA App Download
Download The Global Economics Android App to your mobile or Desktop
Android App
Download The Global Economics IOS App to your mobile or Desktop
IOS App

All Rights Reserved © 2020 | 🇬🇧 The Global Economics, Business Finance Publication - www.theglobaleconomics.uk 🌏

No Result
View All Result
  • About us
  • Awards
  • Magazine
  • Client’s Voice
  • Exclusive Coverage
  • Nominate
  • Login
  • Sign Up

All Rights Reserved © 2020 | 🇬🇧 The Global Economics, Business Finance Publication - www.theglobaleconomics.uk 🌏

Welcome Back!

Sign In with Facebook
Sign In with Linked In
OR

Login to your account below

Forgotten Password? Sign Up

Create New Account!

Sign Up with Facebook
Sign Up with Linked In
OR

Fill the forms below to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In
-
00:00
00:00

Queue

Update Required Flash plugin
-
00:00
00:00
Go to mobile version